Aegla BioTherapeutics Announces $45M Registered Direct Offering Priced At A Premium To Market
AUSTIN, Texas, May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as